Great Valley Advisor Group Inc. Purchases 7,353 Shares of Sanofi (NASDAQ:SNY)

Great Valley Advisor Group Inc. grew its holdings in shares of Sanofi (NASDAQ:SNY) by 11.4% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 71,700 shares of the company’s stock after purchasing an additional 7,353 shares during the quarter. Great Valley Advisor Group Inc.’s holdings in Sanofi were worth $3,479,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in SNY. Frazier Financial Advisors LLC purchased a new position in Sanofi during the fourth quarter valued at $28,000. Larson Financial Group LLC lifted its position in shares of Sanofi by 480.8% during the 1st quarter. Larson Financial Group LLC now owns 604 shares of the company’s stock valued at $29,000 after buying an additional 500 shares in the last quarter. Register Financial Advisors LLC bought a new position in shares of Sanofi during the 1st quarter valued at approximately $29,000. McIlrath & Eck LLC grew its stake in shares of Sanofi by 143.3% during the 4th quarter. McIlrath & Eck LLC now owns 613 shares of the company’s stock valued at $30,000 after acquiring an additional 361 shares during the period. Finally, Johnson Financial Group Inc. purchased a new stake in Sanofi in the 4th quarter worth approximately $31,000. Institutional investors own 10.04% of the company’s stock.

Wall Street Analyst Weigh In

SNY has been the topic of several analyst reports. StockNews.com downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Monday. Argus lifted their target price on shares of Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $57.50.

Sanofi Trading Up 0.3 %

SNY stock traded up $0.18 during midday trading on Wednesday, reaching $53.76. 787,703 shares of the company traded hands, compared to its average volume of 2,128,490. The firm has a market capitalization of $136.16 billion, a price-to-earnings ratio of 26.92, a P/E/G ratio of 1.52 and a beta of 0.59. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. The business has a 50 day moving average of $50.02 and a 200-day moving average of $48.74. Sanofi has a 52-week low of $42.63 and a 52-week high of $55.72.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Thursday, July 25th. The company reported $0.93 EPS for the quarter, topping the consensus estimate of $0.88 by $0.05. The company had revenue of $10.75 billion during the quarter, compared to analyst estimates of $16.86 billion. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. Sanofi’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.95 earnings per share. As a group, sell-side analysts expect that Sanofi will post 4.18 earnings per share for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.